Log in

NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

$12.01
-0.65 (-5.13 %)
(As of 01/27/2020 03:22 AM ET)
Today's Range
$11.92
Now: $12.01
$12.72
50-Day Range
$9.41
MA: $10.92
$12.69
52-Week Range
$5.75
Now: $12.01
$14.94
Volume499,118 shs
Average Volume632,375 shs
Market Capitalization$709.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.50 million
Book Value$0.47 per share

Profitability

Net Income$-106,290,000.00
Net Margins-378.70%
Return on Equity-10,351.99%

Miscellaneous

Employees130
Market Cap$709.55 million
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.


Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.56) by $0.06. The biopharmaceutical company earned $6.06 million during the quarter, compared to analyst estimates of $7.80 million. Cytokinetics had a negative return on equity of 10,351.99% and a negative net margin of 378.70%. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

6 equities research analysts have issued 12-month price objectives for Cytokinetics' stock. Their forecasts range from $16.00 to $26.00. On average, they anticipate Cytokinetics' share price to reach $21.50 in the next year. This suggests a possible upside of 79.0% from the stock's current price. View Analyst Price Targets for Cytokinetics.

What is the consensus analysts' recommendation for Cytokinetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

Has Cytokinetics been receiving favorable news coverage?

Media stories about CYTK stock have trended extremely negative on Monday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytokinetics earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Cytokinetics.

Are investors shorting Cytokinetics?

Cytokinetics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 9,400,000 shares, an increase of 6.7% from the December 15th total of 8,810,000 shares. Based on an average trading volume of 840,600 shares, the days-to-cover ratio is presently 11.2 days. Currently, 17.3% of the company's shares are short sold. View Cytokinetics' Current Options Chain.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (amgn), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Mirador Capital Partners LP (0.17%), Louisiana State Employees Retirement System (0.03%), Granite Investment Advisors LLC (0.03%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View Institutional Ownership Trends for Cytokinetics.

Which major investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and Granite Investment Advisors LLC. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

Which major investors are buying Cytokinetics stock?

CYTK stock was purchased by a variety of institutional investors in the last quarter, including Mirador Capital Partners LP and Nisa Investment Advisors LLC. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $12.01.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $709.55 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.

What is Cytokinetics' official website?

The official website for Cytokinetics is http://www.cytokinetics.com/.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  641 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  917
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel